Neumora Therapeutics said on Thursday its experimental drug to treat depression failed to meet the main goal of a late-stage study, sending shares of the company down 82% in premarket trading. The ...
(NASDAQ: NMRA) nosedived by more than 80 percent during pre-market trading following disappointing results from the Phase 3 trial of navacaprant, a drug being developed to treat major depressive ...
s shares plummeted the most on record after the company’s experimental drug for the treatment of major depressive disorder failed to show a benefit in a final-stage study. Patients who received ...
The study did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression ... the contrast in drug and placebo ...
Jan 2 (Reuters) - Neumora Therapeutics' (NMRA.O), opens new tab shares tumbled more than 80% on Thursday after its experimental depression drug failed to reduce symptoms such as sadness and ...
s shares plummeted the most on record after the company’s experimental drug for the treatment of ... significant improvement in a measurement of depression symptoms, the company said Thursday.
Studies show that therapy alone can be as effective as medication for mild to moderate depression, and when combined with medication, the benefits often exceed those of either treatment alone 1 .
It is the first drug to have an impact on the symptoms of manic depression since the introduction of lithium more than 50 years ago. In international trials over the past two years, daily doses of ...